This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lavarino, C. Articles by Zunino, F. Search for Related Content PubMed PubMed Citation Articles by Lavarino, C. Articles by Zunino, F.

p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma

From the Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan; Istituto di Clinica Ostetrica e Ginecologica, Università Cattolica Sacro Cuore, Rome; and Ospedale San Gerardo, Monza, Italy.

Address reprint requests to Silvana Pilotti, MD, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy; email pilotti@ istitutotumori.mi.it.

PURPOSE: The p53 gene plays a critical role in cellular response to DNA damage and has been implicated in the response to platinum compounds in ovarian carcinoma patients. Because taxanes could induce p53-independent apoptosis, we assessed the relevance of p53 gene status to response in ovarian carcinoma patients receiving paclitaxel and platinum-containing chemotherapy.

PATIENTS AND METHODS: Forty-eight previously untreated patients with advanced disease received standard paclitaxel/platinum-based chemotherapy. In tumor specimens collected at the time of initial surgery, before therapy, p53 gene status and expression were examined by single-strand conformation polymorphism, sequence analysis, and immunohistochemical analysis. Microsatellite instability analysis was performed on available samples from 30 patients.

RESULTS: Thirty-four (71%) of the 48 patients had a clinical response. Pathologic complete remission was documented in 13 (27%) of 48 patients. p53 mutations were detected in 29 (60%) of 48 tumors. Among the patients with mutant p53 tumors, 25 patients (86%) responded to chemotherapy. Only nine (47%) of 19 patients with wild-type p53 tumors responded to the same treatment. The overall response rate and the complete remission rate were significantly higher among patients with mutant p53 tumors than among patients with wild-type p53 tumors (P = .008). Most of the tested tumors not associated with complete remission (10 of 12 tumors) were also characterized by microsatellite instability. The complete remission rate was higher among patients with tumors without microsatellite instability (five of seven patients).

CONCLUSION: In contrast to the limited efficacy of treatment with paclitaxel in combination with standard platinum doses against wild-type p53 ovarian tumors, patients with mutant p53 ovarian tumors were more responsive to paclitaxel-based chemotherapy. The pattern of response to chemotherapy containing paclitaxel is different from that associated with high-dose cisplatin therapy. Determining p53 mutational status can be useful in predicting therapeutic response to drugs effective in ovarian carcinoma.

This article has been cited by other articles:

				F. Bartel, J. Jung, A. Bohnke, E. Gradhand, K. Zeng, C. Thomssen, and S. Hauptmann Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival Clin. Cancer Res., January 1, 2008; 14(1): 89 - 96. [Abstract] [Full Text] [PDF]

				S. Mabuchi, D. A. Altomare, M. Cheung, L. Zhang, P. I. Poulikakos, H. H. Hensley, R. J. Schilder, R. F. Ozols, and J. R. Testa RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model Clin. Cancer Res., July 15, 2007; 13(14): 4261 - 4270. [Abstract] [Full Text] [PDF]

				M. Bagnoli, E. Balladore, E. Luison, P. Alberti, F. Raspagliesi, B. Marcomini, S. Canevari, and D. Mezzanzanica Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment Mol. Cancer Ther., February 1, 2007; 6(2): 762 - 772. [Abstract] [Full Text] [PDF]

				F. Vikhanskaya, M. M. Siddique, M. Kei Lee, M. Broggini, and K. Sabapathy Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs Clin. Cancer Res., June 15, 2005; 11(12): 4348 - 4356. [Abstract] [Full Text] [PDF]

				A. Gadducci, E. Sartori, F. Landoni, P. Zola, T. Maggino, A. Maggioni, S. Cosio, E. Frassi, M. T. LaPresa, L. Fuso, et al. Relationship Between Time Interval From Primary Surgery to the Start of Taxane- Plus Platinum-Based Chemotherapy and Clinical Outcome of Patients With Advanced Epithelial Ovarian Cancer: Results of a Multicenter Retrospective Italian Study J. Clin. Oncol., February 1, 2005; 23(4): 751 - 758. [Abstract] [Full Text] [PDF]

				L. Licitra, S. Suardi, P. Bossi, L.D. Locati, L. Mariani, P. Quattrone, S. Lo Vullo, M. Oggionni, P. Olmi, G. Cantu, et al. Prediction of TP53 Status for Primary Cisplatin, Fluorouracil, and Leucovorin Chemotherapy in Ethmoid Sinus Intestinal-Type Adenocarcinoma J. Clin. Oncol., December 15, 2004; 22(24): 4901 - 4906. [Abstract] [Full Text] [PDF]

				D. Mezzanzanica, E. Balladore, F. Turatti, E. Luison, P. Alberti, M. Bagnoli, M. Figini, A. Mazzoni, F. Raspagliesi, M. Oggionni, et al. CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma Clin. Cancer Res., August 1, 2004; 10(15): 5202 - 5214. [Abstract] [Full Text] [PDF]

				L. Havrilesky, K. M. Darcy, H. Hamdan, R. L. Priore, J. Leon, J. Bell, and A. Berchuck Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., October 15, 2003; 21(20): 3814 - 3825. [Abstract] [Full Text] [PDF]

				K. Ott, H. Vogelsang, J. Mueller, K. Becker, M. Muller, U. Fink, J. R. Siewert, H. Hofler, and G. Keller Chromosomal Instability Rather Than p53 Mutation Is Associated with Response to Neoadjuvant Cisplatin-based Chemotherapy in Gastric Carcinoma Clin. Cancer Res., June 1, 2003; 9(6): 2307 - 2315. [Abstract] [Full Text] [PDF]

				P. A. Vasey, L. N. Shulman, S. Campos, J. Davis, M. Gore, S. Johnston, D. H. Kirn, V. O'Neill, N. Siddiqui, M. V. Seiden, et al. Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian Cancer J. Clin. Oncol., March 15, 2002; 20(6): 1562 - 1569. [Abstract] [Full Text] [PDF]

				P. B. Cassidy, P. J. Moos, R. C. Kelly, and F. A. Fitzpatrick Cyclooxygenase-2 Induction by Paclitaxel, Docetaxel, and Taxane Analogues in Human Monocytes and Murine Macrophages: Structure-Activity Relationships and Their Implications Clin. Cancer Res., March 1, 2002; 8(3): 846 - 855. [Abstract] [Full Text] [PDF]

				N. Keshelava, J. J. Zuo, P. Chen, S. N. Waidyaratne, M. C. Luna, C. J. Gomer, T. J. Triche, and C. P. Reynolds Loss of p53 Function Confers High-Level Multidrug Resistance in Neuroblastoma Cell Lines Cancer Res., August 1, 2001; 61(16): 6185 - 6193. [Abstract] [Full Text] [PDF]